5 completed, 2 terminated. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 4 | Completed 2, Terminated 2 |
Follow forodesine: new trials by email Literature Review of forodesine trials Research Report on forodesine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. Forodesine - Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia | Phase 1 / Phase 2 | Terminated | Mundipharma Research Limited | 2 | 2009-03-01 | 2012-10-24 |
| Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia Forodesine - B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Mundipharma Research Limited | 1 | 2008-07-01 | 2010-03-31 |
| Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Forodesine 200 mg - Cutaneous T-cell Lymphoma (CTCL), | Phase 2 | Completed | BioCryst Pharmaceuticals | 144 | 2007-07-01 | 2012-01-23 |
| Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) forodesine hydrochloride (BCX-1777) - Leukemia, Lymphocytic, Chronic | Phase 2 | Completed | BioCryst Pharmaceuticals | 8 | 2005-06-01 | 2012-02-08 |
| Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia forodesine hydrochloride (BCX-1777) - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | BioCryst Pharmaceuticals | 20 | 2004-09-01 | 2012-01-20 |
| Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia forodesine hydrochloride (BCX-1777) - Leukemia, T-Cell | Phase 2 | Completed | BioCryst Pharmaceuticals | 20 | 2004-03-01 | 2012-01-19 |
| Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas BCX-1777 - Leukemia, Lymphocytic, Lymphoma | Phase 1 / Phase 2 | Completed | BioCryst Pharmaceuticals | 71 | 2001-08-01 | 2006-01-13 |
Leukemia (4) · Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Burkitt Lymphoma (1) · Leukemia, Lymphoid (1) · Leukemia, T-Cell (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
BioCryst Pharmaceuticals (5) · Mundipharma Research Limited (2)
United States (5) · Austria (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Finland (1) · Georgia (1) · Switzerland (1)
Alan B Fleischer, Jr., MD (1) · Andre Goy, MD (1) · Andrei R Shustov, MD (1) · Andres Forero-Torres, M.D. (1) · Deborah A. Thomas, M.D. (1) · Elise Olsen, MD (1) · Farhad Ravandi, MD (1) · Francesco Turturro, MD (1) · Francine Foss, MD (1) · Gary S. Wood, MD (1) · Larisa Geskin, MD (1) · Madeleine Duvic, MD (1) · Miles Prince, MD (1) · Nancy Bartlett, MD (1) · Nashat Gabrail, MD (1)
2008 (1)